A prospective, clinical interventional, multicenter cohort study will be necessary to confirm the relationships between the levels of anti-gAChR Abs, serum biomarkers (including VEGF and endostatin), and autonomic function (including the severity of GI dysmotility in SSc) versus the outcomes of immunotherapies. Here, COL18A1 is linked to Gastrointestinal dysmotility.